IONIS PHARMACEUTICALS INC

Ionis Pharmaceuticals is a commercial-stage biotechnology company that discovers, develops, and delivers RNA-targeted medicines to treat serious and life-threatening human diseases. Its core therapeutic focus areas include neurology, cardiometabolic disorders, and select areas of high unmet patient need. The company's marketed product portfolio features therapies such as Tryngolza, Dawnzera, Wainua, Spinraza, Qalsody, Tegsedi, and Waylivra. These treatments serve patients suffering from severe conditions, including familial chylomicronemia syndrome, hereditary angioedema, hereditary transthyretin-mediated amyloidosis polyneuropathy, spinal muscular atrophy, and amyotrophic lateral sclerosis. In addition to commercializing products independently in select markets, the company partners with global pharmaceutical firms to co-develop and distribute its therapies worldwide.

The company's commercialized products and clinical operations reach patients across multiple international markets, with regulatory approvals and active distribution agreements spanning the United States, the European Union, Canada, China, Japan, the United Kingdom, and Brazil. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Ionis Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of February 19, 2026, we employed 1,402 people, the vast majority of whom reside in the U.S.”